Evidence map›Paper›PMID 33199755›Full record

ArticleScientific reports2020

Metabolic interaction between amino acid deprivation and cisplatin synergistically reduces phosphoribosyl-pyrophosphate and augments cisplatin cytotoxicity.

Nisreen Wahwah, Debanjan Dhar, Hui Chen, Shunhui Zhuang, Adriano Chan, Darren E Casteel, Hema Kalyanaraman, Renate B Pilz, Gerry R Boss

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nisreen WahwahDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Debanjan DharDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Hui ChenDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Shunhui ZhuangDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Adriano ChanDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Darren E CasteelDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Hema KalyanaramanDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Renate B PilzDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA.
Gerry R BossDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093-0652, USA. gboss@health.ucsd.edu.
University of California, San Diego · US

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Mechanisms of vascular pathology from abnormal protein kinase G signalingR01HL132141 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PILZ, RENATE B · 2016 to 2025
$4.5M
REGULATION OF GENE EXPRESSION BY cGMP and PKG IN BONER01AR051300 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PILZ, RENATE B · 2004 to 2014
$3.1M
Targeting defective NO/cGMP signaling as novel therapy for diabetic osteoporosisR01AR068601 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PILZ, RENATE B · 2016 to 2020
$1.8M
NCATS NIH HHS KL2 TR001444NHLBI NIH HHS R01 HL132141NIAMS NIH HHS R01 AR051300NIAMS NIH HHS R01 AR068601NIH HHS R01-AR068601NINDS NIH HHS P30 NS047101
6 · The paper itself

Abstract

Cisplatin is a mainstay of cancer chemotherapy. It forms DNA adducts, thereby activating poly(ADP-ribose) polymerases (PARPs) to initiate DNA repair. The PARP substrate NAD

Indexed as

ApoptosisAmino AcidsAnimalsAntineoplastic AgentsCarcinoma, HepatocellularCell ProliferationCisplatinHumansLiver NeoplasmsMaleMiceMice, NudePhosphoribosyl PyrophosphateTumor Cells, CulturedXenograft Model Antitumor AssaysAmino AcidsAntineoplastic AgentsCisplatinPhosphoribosyl Pyrophosphate

Identifiers

PMID33199755
PMCPMC7670436
OpenAlexW3098565930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.